William K. Oh, MD

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

The arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the hormone-sensitive setting of prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel (Taxotere) in patients with metastatic castration-resistant prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).

William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the challenges that remain with the use of docetaxel to treat patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the safety profile of docetaxel when administered to patients with prostate cancer.

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

William K. Oh, MD, professor of Medicine, Hematology, and Medical Oncology, and Urology, Mount Sinai Hospital, discusses a global study aimed at recognizing symptom burden in patients with advanced prostate cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses recent updates in bladder cancer treatment.

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC).

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.